Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells

Gynecologic Oncology

Volumn 85, Issue 3, 2002, Pages 498-506

  Dardes, R C ^a,b   Schafer, J MacGregor ^b   Pearce, S Timm ^b   Osipo, C ^b   Chen, B ^b   Jordan, V C ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Athymic mice; ECC 1 cells; Endometrial cancer; Raloxifene; Tamoxifen

Indexed keywords

ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; LUCIFERASE; MESSENGER RNA; ONCOPROTEIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER TRANSPLANTATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENE CONTROL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NORTHERN BLOTTING; NUDE MOUSE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 0036087615     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2002.6659     Document Type: Article

References (46)

1. Selective estrogen receptor modulation: A personal perspective
2. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
3. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
4. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
5. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation
6. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation
7. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats
8. Novel agents to modulate oestrogen action
9. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351
10. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex
11. Effect of raloxifene after tamoxifen on breast and endometrial cancer growth
12. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.hc1, in metastatic breast cancer
13. Effects of the antiestrogens tamoxifen, and LY353381.HC1 (arzoxifene) on endometrial cancer growth
14. Necropsy diagnosis of endometrial cancer and detection-bias in case/control studies
15. Hormonal control of growth of human endometrial carcinoma in the nude mouse model
16. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen
17. Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue
18. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor
19. Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells
20. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines
21. A simple, rapid and sensitive DNA assay procedure
22. Antiestrogenic action of toremifene on hormone-dependent, independent, and heterogeneous breast tumor growth in the athymic mouse
23. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth
24. Hormone replacement therapy and cancer risk
25. Menopause, hormone replacement therapy and cancer
26. Future directions in endocrine therapy for the treatment and prevention of breast cancer
27. Carcinoma of the endometrium
28. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
29. Estrogen- and antiestrogen-responsiveness of HECIA endometrial adenocarcinoma cells in culture
30. Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line)
31. Proliferation and responsiveness to estrogen of human endometrial cancer cells under serum-free culture conditions
32. Action of "pure" antiestrogens in inhibiting estrogen receptor action
33. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators
34. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
35. Estrogen response elements can mediate agonist activity of anti-estrogens in human endometrial Ishikawa cells
36. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors
37. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor
38. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells
39. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta
40. Raloxifene hydrochloride
41. Molecular targets for breast cancer therapy and prevention
42. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN
43. Expression of keratinocyte growth factor receptor compared with that of epidermal growth factor receptor and erbB-2 in endometrial adenocarcinoma
44. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status
45. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer
46. Estrogen and aryl hydrocarbon responsiveness of ECC-1 endometrial cancer cells